This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
After Plunging 59.2% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics, Inc. (FULC)
by Zacks Equity Research
Fulcrum Therapeutics, Inc. (FULC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Earnings Preview: Fulcrum Therapeutics, Inc. (FULC) Q1 Earnings Expected to Decline
by Zacks Equity Research
Fulcrum Therapeutics, Inc. (FULC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Fulcrum (FULC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Fulcrum (FULC) stock based on the movements in the options market lately.
Fulcrum Therapeutics, Inc. (FULC) Stock Jumps 5.7%: Will It Continue to Soar?
by Zacks Equity Research
Fulcrum Therapeutics, Inc. (FULC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Does Fulcrum Therapeutics, Inc. (FULC) Have the Potential to Rally 179% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 178.8% in Fulcrum Therapeutics, Inc. (FULC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 10.77% and 26.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Vericel Corporation (VCEL) Q4 Earnings Miss Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of -47.06% and 0.24%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Reata (RETA) Stock Up Following Q3 Earnings & Sales Beat
by Zacks Equity Research
Reata (RETA) beats estimates for earnings and sales. An advisory committee meeting is scheduled on Dec 8 to discuss bardoxolone NDA.
Axsome (AXSM) Q3 Earnings Top, Pre-Launch Activities Continue
by Zacks Equity Research
Axsome Therapeutics (AXSM) reports a narrower-than-expected Q3 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.
Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 10.94% and 68.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Galera (GRTX) Tanks As Oral Mucositis Study Fails to Meet Goal
by Zacks Equity Research
Galera's (GRTX) phase III ROMAN study on avasopasem for treating radiotherapy-induced severe oral mucositis in patients with head and neck cancer fails to meet its primary endpoint. Shares fall.
Radius' (RDUS) Study on Tymlos for Osteoporosis in Men Meets Goal
by Zacks Equity Research
Radius (RDUS) reports positive top-line results from the ATOM study evaluating Tymlos (abaloparatide) subcutaneous injection for use in men with osteoporosis. The study met the primary endpoint.
Oyster Point's (OYST) Tyrvaya Gets FDA Nod for Dry Eye Disease
by Zacks Equity Research
The FDA approves Oyster Point's (OYST) Tyrvaya nasal spray for the treatment of the signs and symptoms of dry eye disease.
Can Fulcrum Therapeutics, Inc. (FULC) Climb 31% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 30.9% upside potential for Fulcrum Therapeutics, Inc. (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 7.69% and 62.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Fulcrum Therapeutics, Inc. (FULC) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Fulcrum Therapeutics, Inc. (FULC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 18.18% and 119.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 12.33% and 153.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Kodiak Sciences (KOD) Q3 Earnings Miss, KSI-301 in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss in the third quarter of 2020. The company is progressing well with the development of its lead pipeline candidate KSI-301.
Novavax (NVAX) Loss Widens in Q3, Revenues Lag Estimates
by Zacks Equity Research
Novavax's (NVAX) bottom line deteriorates year over year in the third quarter of 2020. Revenues fall shy of estimates as well. Stock dips in after-hours trading.
Fulcrum Therapeutics' (FULC) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Fulcrum Therapeutics (FULC).
Puma (PBYI) Down 8% on Q3 Earnings Lag, Nerlynx Sales View Cut
by Zacks Equity Research
Puma Biotech (PBYI) falls more than 8% as it misses on both earnings and revenues in the third quarter of 2020. The company trims its 2020 revenue guidance for Nerlynx.
Why Fulcrum Therapeutics (FULC) Might Surprise This Earnings Season
by Zacks Equity Research
Fulcrum Therapeutics (FULC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Axsome's (AXSM) Q3 Earnings In Line, Pipeline Progresses
by Zacks Equity Research
Axsome (AXSM) earnings meet estimates in the third quarter. The company stretches the timeline for the NDA filing for AXS-05 and AXS-07. Shares fall.
Editas' (EDIT) Earnings Rise Y/Y in Q3, EDIT-101 in Focus
by Zacks Equity Research
Editas' (EDIT) bottom line grows year over year in the third quarter while revenues beat estimates. Stock rises is after-hours trading.